|
|
Tau has been shown to be important in the development of Alzheimers Disease.Eradication of Tau accomplished without reducing levels of nontarget cytokine.JACKSON CENTER, PA / ACCESSWIRE / February 1, 2022 / Halberd Corporation OTC PINK:HALB has demonstrated the ability to selectively reduce and control the level of one element in a heterogeneous mixture containing... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / January 25, 2022 / Greetings From The CEO And Staff At HALBERD CORPORATION! OTC PINK:HALBFirst of all I want to wish all of our shareholders and constituents a Very Healthy, Happy and Prosperous New Year!2021 OVERVIEW AND ACHIEVEMENTSHalberd continued its R&D strategy to focus on biomedical... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / January 13, 2022 / Halberd, Inc. OTC PINK:HALB "HALB" or the "Company", an innovative biotech company focused on developing treatments for difficulttocure debilitating diseases, today announces that they have been able to successfully eliminate Beta Amyloid and Interleukin4 IL4 from synthetic cerebral spinal fluid CSF in its latest invitro... Lire le communiqué |
|
| |
|
| |
|
|
Halberd to bid on Additional Federal Contracts with the Federal GovernmentJACKSON CENTER, PA / ACCESSWIRE / January 5, 2022 / Halberd Corporation OTC PINK:HALB is now registered with the Federal Governments System for Award Management allowing Halberd to bid on Federal contracts and conduct business with the Federal government in the areas of Research and Development in Biotechnology, and Food... Lire le communiqué |
|
| |
|
| |
|
|
Latest Testing Eliminates Interleukin2 From Cerebral Spinal FluidJACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation OTC Pink:HALB has been able to successfully eliminate Interleukin2 IL2 from synthetic cerebral spinal fluid CSF in preliminary testing. Halberd also successfully replicated its previous successful elimination of each of the inflammatory cytokines listed... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / December 15, 2021 / Halberd Corporation OTC PINK:HALB has demonstrated 100% eradication of Interleukin12 IL12 from synthetic cerebral spinal fluid CSF in preliminary testing. Interleukin12 is a proinflammatory cytokine which has recently been identified at elevated levels in patients with Alzheimers Disease or mild cognitive impairment. Halberds demonstrated... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2021 / Halberd Corporation OTC PINK:HALB has demonstrated 100% eradication of Interleukin1 IL1 from synthetic cerebral spinal fluid CSF in preliminary testing. Interleukin1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimers Disease. Halberds demonstrated ability to control the levels of IL1, coupled with... Lire le communiqué |
|
| |
|
| |
